NCT01186731View on ClinicalTrials.gov

Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

December 31, 2011

Conditions
Pancreatic Cancer
Interventions
DRUG

Liposome Entrapped Docetaxel (LE-DT)

110 mg/m2 (IV)in vein on day 1 of each 21 day cycle , 6 cycles, until progression or unacceptable toxicity

Trial Locations (1)

20007-2197

Lombardi Cancer Center, Georgetown University Medical Center, Washington D.C.

Sponsors
All Listed Sponsors
lead

INSYS Therapeutics Inc

INDUSTRY